gastrointestinal tract News
-
Study results presented at AGW show Atmo Gas Capsule can be used to assess regional gastrointestinal transit in healthy adults
A Monash University comparative study has found Atmo Biosciences’ novel ingestible gas-sensing capsule to be similar to a validated wireless motility capsule (WMC) when assessing regional gastrointestinal transit time in healthy adults. Findings from the study, led by Professor Peter Gibson, are being presented in a poster at Australian Gastroenterology Week (AGW), being held virtually ...
-
Microbiologists’ work adds to research on microbiome fungi and childhood disease
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. Much of the research has focused on gut bacteria and viruses, leaving a third factor - fungi - little studied. An international consortium of scientists has conducted the first large-scale ...
-
EsoCap featured in the Medicine Maker
“We are extremely pleased that The Medicine Maker is reporting on how EsoCap’s unique and innovative topical drug delivery system offers new treatment options for diseases of the esophagus,” said Isabelle Racamier, EsoCap AG CEO. “The interview is a great opportunity to highlight the challenges of esophageal disease and how EsoCap is innovating localized esophagus ...
By EsoCap AG
-
Esocap Featured In Fierce Pharma
“We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and the current Phase II program, as well as further use of its platform in additional indications,” said Isabelle Racamier, EsoCap AG CEO. “This strengthens our resolve to bring a major improvement to the lives of patients using ...
By EsoCap AG
-
Human trials underway for first generation Atmo Gas Capsule
Two human trials of Atmo Biosciences’ ingestible gas-sensing capsule have begun. The first trial is being conducted at Monash University and the Alfred Hospital in Melbourne, Australia, in collaboration with the research team led by Professor Peter Gibson and Professor Jane Muir. The trial will investigate motility and transit time through the gastrointestinal tract for the Atmo Gas ...
-
EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application technology for the upper ...
By EsoCap AG
-
5 More Bad Bugs to Watch Out For
From vicious viruses to felonious fungi, these bad bugs are wanted for a wide array of sickening crimes. Cryptosporidium Despite breaking most of the rules, Cryptosporidium is a regular at the local recreation center. He can’t resist infecting innocent swimmers, but he can resist chlorine. Much like the diarrhea he leaves in his wake, Cryptosporidium strikes without warning and moves ...
-
Esocap announces publication of “Functionality and Acceptance of the EsoCap System - a Novel Film-Based Drug Delivery Technology: Results of an In Vivo Study“
EsoCap has announced that scientists from the University of Greifswald have published exciting data demonstrating the high level of acceptance of its novel drug delivery technology enabling targeted and long-lasting local therapy of the esophagus (Rosenbaum et al., Pharmaceutics 2021, 13, 828). In contrast to tablets, capsules or viscous fluids, which are known for short esophageal transit ...
By EsoCap AG
-
Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). “There is a high unmet medical ...
By Camurus AB
-
EsoCap announces issue of U.S. patent for its smart application technology in the upper gastrointestinal tract
EsoCap AG has announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,744,095 on August 18, 2020. The patent is directed at the smart application technology enabling specific sitedirected treatment of several diseases of the esophagus. “Issue of the U.S. patent is a major milestone confirming the novelty of EsoCap’s proprietary ...
By EsoCap AG
-
Check-Cap Announces Grant of Patent Covering C-Scan`s Proprietary Tracking Technology in the U.S. and Additional Major Market Territories
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the United States Patent and Trademark Office (USPTO), has issued a ...
-
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburn EsoCap is currently conducting a randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients in four European countries with its lead candidate ESO-101 To help raise awareness of the medical condition, EsoCap supports EUREOS and ...
By EsoCap AG
-
EsoCap Announces Publication “Development of a HotMelt Extrusion-Based Spinning Process to Produce Pharmaceutical Fibers and Yarns”
EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. The rapidly dissolving yarn is ...
By EsoCap AG
-
Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery ...
By Suono Bio
-
Who can benefit from an adjustable gastric band implant?
Who can benefit from an adjustable gastric band implant? Adults between the ages of 18 and 60 years with morbid obesity (BMI of > 40) or severe obesity (BMI of > 35) with at least one complication (diabetes, hypertension, sleep apnea syndrome, joint disorders) People who have already tried to lose weight without success despite receiving specialized medical care for several months ...
-
EndoClot Expands GI Hemostasis Portfolio With Launch of EndoClot® Adhesive
EndoClot Plus, Inc., a privately held medical device company founded by surgeons and biomaterial scientists announces the CE approval of EndoClot® Adhesive manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China. The product will be made available for discussion during the upcoming Digestive Disease Week held in Washington DC, June 2-5, 2018. EndoClot® Adhesive is a single-use ...
-
Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of drugs, including ...
By Suono Bio
-
Check-Cap Announces FDA Approval of Amended IDE Application for Pivotal Study of C-Scan
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, thefirst and onlypatient-friendly preparation-freescreening test to detect polypsbeforethey may transform into colorectal cancer (CRC), today announced that the Company has received approval from the U.S. Food and Drug Administration ...
-
Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq`s Minimum Bid Price Requirement
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), announces that onJune 22, 2022, it received a letter from The Nasdaq Stock Market LLC ...
-
EndoClot Plus, Inc. Announces FDA Clearance of GI Submucosal Lifting Product
EndoClot Plus, Inc. (EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot® Submucosal Injection Agent (EndoClot® SIA) manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China. This product is expected to be commercially available in the United States beginning in May 2020 and later this year in several international markets. EndoClot® ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you